Literature DB >> 31415723

Botulinum toxin and surgical intervention in children and adolescents with cerebral palsy: who, when and why do we treat?

Jane Valentine1, Sue-Anne Davidson2, Natasha Bear3, Eve Blair4, Roslyn Ward5, Ashleigh Thornton1, Katherine Stannage6, Linda Watson7, David Forbes8, Catherine Elliott5.   

Abstract

INTRODUCTION: This audit aimed to increase understanding of the long-term outcomes of evidence-based medical and surgical interventions to improve gross motor function in children and adolescents with Cerebral Palsy.
METHODS: Retrospective audit of a birth cohort (2000-2009) attending a tertiary service in Western Australia.
RESULTS: The cohort comprises 771 patients aged 8 to 17 years. Percentage of children receiving no Botulinum Toxin treatments in each Gross Motor Functional Classification System level was: I: 40%, II: 26%, III: 33%, IV: 28% and V: 46%. Of the total cohort, 53% of children received 4 or less Botulinum Toxin treatments and 3.7% received more than 20 treatments. Statistically significant difference in the rate of use of Botulinum Toxin pre and post-surgery (p < 0.001) was documented. Children levels IV and V had 5 times the odds of surgery compared to children levels I-III (Odds Ratio 5.2, 95% Confidence Interval 3.5 to 7.8, p < 0.001). For 578 (75%) of participants the last recorded level was the same as the first.
CONCLUSION: This audit documents medical intervention by age and Gross Motor Functional Classification System level in a large cohort of children with cerebral palsy over time and confirms stability of the level in the majority.IMPLICATIONS FOR REHABILITATIONThe information from this audit may be of use in discussions with families regarding the timing and use of Botulinum toxin and surgical intervention for motor function in children and adolescents with Cerebral Palsy.Long term use of Botulinum Toxin within an integrated evidence-based clinical program is not associated with loss of gross motor function in the long term as evidenced by the maintenance of Gross Motor Functional Classification System stability.

Entities:  

Keywords:  Cerebral palsy; botulinum toxin; children; gross motor function classification; orthopedic surgery

Mesh:

Substances:

Year:  2019        PMID: 31415723     DOI: 10.1080/09638288.2019.1644381

Source DB:  PubMed          Journal:  Disabil Rehabil        ISSN: 0963-8288            Impact factor:   3.033


  6 in total

Review 1.  Principles of Medical and Surgical Treatment of Cerebral Palsy.

Authors:  Eric M Chin; Hilary E Gwynn; Shenandoah Robinson; Alexander H Hoon
Journal:  Neurol Clin       Date:  2020-05       Impact factor: 3.806

2.  Comment on: "Botulinum Toxin in the Management of Children with Cerebral Palsy".

Authors:  Katherine Langdon; Lisa Copeland; Priya Edwards; Kate Rodwell; Kim McLennan; Theresa Carroll; Sasaka Bandaranayake; Adam Scheinberg; Mary-Clare Waugh; Heather Burnett; Neil Wimalasundera; Sabine Hennel; Eewei Lim; Steve O'Flaherty
Journal:  Paediatr Drugs       Date:  2019-12       Impact factor: 3.022

3.  Authors' Reply to K. Langdon and Colleagues' Comment on: "Botulinum Toxin in the Management of Children with Cerebral Palsy".

Authors:  Iqbal Multani; Jamil Manji; Tandy Hastings-Ison; Abhay Khot; Kerr Graham
Journal:  Paediatr Drugs       Date:  2019-12       Impact factor: 3.022

4.  Orthopedic surgical procedures in 3,305 children and young adults with cerebral palsy: a register-based cohort study.

Authors:  Anna Telléus; Nikolaos Kiapekos; Johan Von Heideken; Philippe Wagner; Eva Broström; Gunnar Hägglund; Per Åstrand
Journal:  Acta Orthop       Date:  2022-05-23       Impact factor: 3.925

Review 5.  Over 25 Years of Pediatric Botulinum Toxin Treatments: What Have We Learned from Injection Techniques, Doses, Dilutions, and Recovery of Repeated Injections?

Authors:  Heli Sätilä
Journal:  Toxins (Basel)       Date:  2020-07-06       Impact factor: 4.546

6.  A prospective study investigating gross motor function of children with cerebral palsy and GMFCS level II after long-term Botulinum toxin type A use.

Authors:  Jane Valentine; Sue-Anne Davidson; Natasha Bear; Eve Blair; Lisa Paterson; Roslyn Ward; David Forbes; Catherine Elliott
Journal:  BMC Pediatr       Date:  2020-01-06       Impact factor: 2.125

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.